Skip to main content
Top
Published in: Journal of Translational Medicine 1/2018

Open Access 01-12-2018 | Commentary

Biobanks and scientists: supply and demand

Authors: Angelo Virgilio Paradiso, Maria Grazia Daidone, Vincenzo Canzonieri, Alfredo Zito

Published in: Journal of Translational Medicine | Issue 1/2018

Login to get access

Abstract

The biobanks, providers of biospecimens, and the scientists, users of biological material, are both strategic actors in translational medicine but the communication about those two subjects seems to be delicate. Recently, biobank managers from US and Europe stressed the danger of underuse of biospecimens stored in their biobanks thus stimulating the debate about innovative ways to collect samples and to communicate their availability. We hypothesize that the already stored collections meet the interest of present scientists only in specific situations. Serial biospecimens from patients with large associated clinical data concerning voluptuary habits, environmental exposure, anthropomorphic information are needed to meet the even more specific projects the scientists are planning. The hypothesis of activation of specific sections in ranked journals aimed to facilitate the communication between partners interested in finding/collecting ad hoc biospecimens is discussed.
Literature
1.
go back to reference Shaw DM, Elger BS, Colledge F. What is a biobank? Differing definitions among biobank stakeholders. Clin Genet. 2014;85(3):223–7.CrossRefPubMed Shaw DM, Elger BS, Colledge F. What is a biobank? Differing definitions among biobank stakeholders. Clin Genet. 2014;85(3):223–7.CrossRefPubMed
2.
go back to reference Watson PH, Barnes RO. A proposed schema for classifying human research biobanks. Biopreserv Biobank. 2011;9(4):327–33.CrossRefPubMed Watson PH, Barnes RO. A proposed schema for classifying human research biobanks. Biopreserv Biobank. 2011;9(4):327–33.CrossRefPubMed
3.
go back to reference Riegman PH, de Jong BW, Llombart-Bosch A. The Organization of European Cancer Institute Pathobiology Working Group and its support of European bio banking infrastructures for translational cancer research. Cancer Epidemiol BiomarkersPrev. 2010;19(4):923–6.CrossRef Riegman PH, de Jong BW, Llombart-Bosch A. The Organization of European Cancer Institute Pathobiology Working Group and its support of European bio banking infrastructures for translational cancer research. Cancer Epidemiol BiomarkersPrev. 2010;19(4):923–6.CrossRef
4.
go back to reference Holub P, Swertz M, Reihs R, van Enckevort D, Müller H, Litton JE. BBMRI-ERIC directory: 515 Biobanks with over 60 million biological samples. Biopreserv Biobank. 2016;14(6):559–62.CrossRefPubMedPubMedCentral Holub P, Swertz M, Reihs R, van Enckevort D, Müller H, Litton JE. BBMRI-ERIC directory: 515 Biobanks with over 60 million biological samples. Biopreserv Biobank. 2016;14(6):559–62.CrossRefPubMedPubMedCentral
5.
go back to reference Vaught J, Rogers J, Carolin T, Compton C. Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. J Natl Cancer Inst Monogr. 2011;42:24–31.CrossRef Vaught J, Rogers J, Carolin T, Compton C. Biobankonomics: developing a sustainable business model approach for the formation of a human tissue biobank. J Natl Cancer Inst Monogr. 2011;42:24–31.CrossRef
6.
go back to reference Patel A. Tissue banking for research-bench to bedside and back–myth, reality or fast fading reality at the dawn of a personalised healthcare era. Cell Tissue Bank. 2011;12(1):19–21.CrossRefPubMed Patel A. Tissue banking for research-bench to bedside and back–myth, reality or fast fading reality at the dawn of a personalised healthcare era. Cell Tissue Bank. 2011;12(1):19–21.CrossRefPubMed
7.
go back to reference Paradiso A, Daidone MG, Riegman P. Introduction to cancer biobanking: why, where, how? Biopreserv Biobank. 2011;9(2):139–40.CrossRefPubMed Paradiso A, Daidone MG, Riegman P. Introduction to cancer biobanking: why, where, how? Biopreserv Biobank. 2011;9(2):139–40.CrossRefPubMed
8.
go back to reference Cadigan RJ, Juengst E, Davis A, Henderson G. Underutilization of specimens in biobanks: an ethical as well as a practical concern? Genet Med. 2014;16(10):738–40.CrossRefPubMedPubMedCentral Cadigan RJ, Juengst E, Davis A, Henderson G. Underutilization of specimens in biobanks: an ethical as well as a practical concern? Genet Med. 2014;16(10):738–40.CrossRefPubMedPubMedCentral
9.
go back to reference Henderson GE, Cadigan RJ, Edwards TP, Conlon I, Nelson AG, Evans JP, et al. Characterizing biobank organizations in the US: results from a national survey. Genome Med. 2013;5(1):3.CrossRefPubMedPubMedCentral Henderson GE, Cadigan RJ, Edwards TP, Conlon I, Nelson AG, Evans JP, et al. Characterizing biobank organizations in the US: results from a national survey. Genome Med. 2013;5(1):3.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Sawyer SJ, Otto JM, Suh KS. Ensuring biobank value through effective utilization. Biopreserv Biobank. 2015;13(6):396–400.CrossRefPubMed Sawyer SJ, Otto JM, Suh KS. Ensuring biobank value through effective utilization. Biopreserv Biobank. 2015;13(6):396–400.CrossRefPubMed
12.
go back to reference Betsou F, Bulla A, Cho SY, Clements J, Chuaqui R, Coppola D, et al. Assays for qualification and quality stratification of clinical biospecimens used in research: a technical report from the ISBER Biospecimen Science Working Group. Biopreserv Biobank. 2016;14(5):398–409.CrossRefPubMedPubMedCentral Betsou F, Bulla A, Cho SY, Clements J, Chuaqui R, Coppola D, et al. Assays for qualification and quality stratification of clinical biospecimens used in research: a technical report from the ISBER Biospecimen Science Working Group. Biopreserv Biobank. 2016;14(5):398–409.CrossRefPubMedPubMedCentral
13.
go back to reference Riondino S, Ferroni P, Spila A, Alessandroni J, D’Alessandro R, Formica V, et al. Ensuring sample quality for biomarker discovery studies—use of ICT tools to trace biosample life-cycle. Cancer Genomics Proteomics. 2015;12(6):291–9.PubMed Riondino S, Ferroni P, Spila A, Alessandroni J, D’Alessandro R, Formica V, et al. Ensuring sample quality for biomarker discovery studies—use of ICT tools to trace biosample life-cycle. Cancer Genomics Proteomics. 2015;12(6):291–9.PubMed
14.
16.
go back to reference Brock A, Huang S. Precision oncology: between vaguely right and precisely wrong. Cancer Res. 2017;77(23):6473–9.CrossRefPubMed Brock A, Huang S. Precision oncology: between vaguely right and precisely wrong. Cancer Res. 2017;77(23):6473–9.CrossRefPubMed
17.
go back to reference Cole A, Cheah S, Dee S, Hughes S, Watson PH. Biospecimen use correlates with emerging techniques in cancer research: impact on planning future biobanks. Biopreserv Biobank. 2012;10(6):518–25.CrossRefPubMed Cole A, Cheah S, Dee S, Hughes S, Watson PH. Biospecimen use correlates with emerging techniques in cancer research: impact on planning future biobanks. Biopreserv Biobank. 2012;10(6):518–25.CrossRefPubMed
18.
go back to reference Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;21(4):116. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;21(4):116.
19.
go back to reference Norlin L, Fransson MN, Eriksson M, Merino-Martinez R, Anderberg M, Kurtovic S, et al. A minimum data set for sharing Biobank samples, information, and data: MIABIS. Biopreserv Biobank. 2012;10(4):343–8.CrossRefPubMed Norlin L, Fransson MN, Eriksson M, Merino-Martinez R, Anderberg M, Kurtovic S, et al. A minimum data set for sharing Biobank samples, information, and data: MIABIS. Biopreserv Biobank. 2012;10(4):343–8.CrossRefPubMed
20.
go back to reference Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, et al. On the behalf of the “dynamic medicine OECI group”. Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. J Exp Clin Cancer Res. 2017;36(1):128.CrossRefPubMedPubMedCentral Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, et al. On the behalf of the “dynamic medicine OECI group”. Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. J Exp Clin Cancer Res. 2017;36(1):128.CrossRefPubMedPubMedCentral
21.
go back to reference Allen D. A failed model. Pathol. 2017;817:301. Allen D. A failed model. Pathol. 2017;817:301.
Metadata
Title
Biobanks and scientists: supply and demand
Authors
Angelo Virgilio Paradiso
Maria Grazia Daidone
Vincenzo Canzonieri
Alfredo Zito
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2018
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-018-1505-8

Other articles of this Issue 1/2018

Journal of Translational Medicine 1/2018 Go to the issue